Redwood Pharma presents positive results from a clinical study with RP501 against dry eye
Stockholm, 31 May 2023. Redwood Pharma AB (publ) announces positive results from the company's clinical study with RP501, a medical technology self-care product being developed for the treatment of dry eye. The results show that RP501 is safe and well-tolerated and that the product produces statistically significant positive results on several subjective efficacy measures, such as burning sensation, stinging and itching.In the study, the safety, tolerability and effect of the treatment were evaluated in people who suffer from dry eye and in contact lens wearers who experience discomfort